News

Individuals and organizations internationally are marking World Alzheimer’s Day, Sept. 21, by focusing efforts on increasing awareness and challenging stigmas about Alzheimer’s, the most common form of dementia. For the seventh consecutive year, September is World Alzheimer’s Month. Every 68 seconds, someone somewhere develops the progressive disease that…

Nuplazid (pimavanserin) is more effective in reducing severe psychotic symptoms — particularly hallucinations and delusions — in Alzheimer’s disease patients than in those with milder symptoms, according to additional Phase 2 clinical trial results. The study, “Pimavanserin in Alzheimer’s Disease Psychosis: Efficacy in Patients with…

The absolute 10-year risk of dementia varies according to age, gender, and common variation in the APOE gene, according to a large-scale Danish study. This discovery may help identify high-risk individuals who may benefit from early targeted intervention to prevent dementia’s development and progression. The study, “Absolute…

Flortaucipir, an investigational imaging agent, was able to efficiently detect Tau protein aggregates and related Alzheimer’s disease brain changes, meeting both of its primary objectives in a Phase 3 trial. Results of the trial revealed that flortaucipir demonstrated great sensitivity in identifying tau-related damage and predicting Alzheimer’s disease diagnosis.

Excessive daytime sleepiness or napping is associated with increased beta-amyloid plaques in the brain, a major characteristic of Alzheimer’s disease, according to a study that followed patients for more than 15 years. The study, “Excessive daytime sleepiness and napping in cognitively normal adults: associations with subsequent amyloid…

Small proteins found in sea anemones can protect nerve cells from the toxic effects of beta-amyloid, a hallmark of Alzheimer’s, and may one day point to a way of treating this disease, a study reports. The research, “A New Iq-Peptide of the Kunitz Type from the Heteractis magnifica Sea…

Latest results from the long-term extension of a Phase 1b study assessing increasing and fixed doses of aducanumab continue to show its potential as a therapy for early or mild Alzheimer’s disease. Similar to previous interim analyses, data collected for up to 48 months reveal that the investigative…

A non-invasive eye exam, similar to those given in eye doctors’ offices, might someday help predict a person’s risk of developing Alzheimer’s disease, a new study suggests. The study, “Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings,” was published in the journal JAMA Ophthalmology. While…

Scientists have discovered why some people who have brain markers of Alzheimer’s disease, such as protein plaques and tangles, do not develop dementia. The reason may lie in the structure of synapses — the points of contact between nerve cells that allow them to communicate. Findings were published in the study,…

ProMIS Neurosciences’ lead therapeutic candidate for Alzheimer’s disease, PMN310, showed an improved safety profile when directly compared to other amyloid-beta directed antibodies, according to preclinical study results. Unlike BAN2401 (Biogen, Eisai) and aducanumab (Biogen), two amyloid-beta directed antibodies both in clinical development, PMN310 did not…